FDA reopens comment period
This article was originally published in The Tan Sheet
Executive Summary
FDA will reopen until May 18 the comment period on issues relating to its regulations for chemistry, manufacturing and controls supplements and other changes to approved marketing applications for human drugs, according to a Federal Register notice slated for publication April 16. The agency conducted a public meeting in February to consider comments on issues it should consider in revising those regulations, as required by the FDA Modernization Act of 1997 (1"The Tan Sheet" Feb. 26, 2007, p. 12)...
You may also be interested in...
FDA Urged To Revise Manufacturing Reg To Increase Flexibility For OTCs
Drug firms have more flexibility changing production protocols for over-the-counter drugs than pharmaceuticals, but the industry would benefit if FDA regulations allowed supplements for OTC products' chemistry, manufacturing and controls to be done without prior approval, an industry representative says
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.